Enterprise Value
734.2M
Cash
4.952M
Avg Qtr Burn
-17.96M
Short % of Float
1.36%
Insider Ownership
5.69%
Institutional Own.
53.21%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MT-8421 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
MT-0169 (TAK-169) (CD38) Details Multiple myeloma, Extramedullary myeloma | Phase 1 Update | |
MT-6402 Details Solid tumor/s, Cancer | Phase 1 Update | |
MT-3724 (CD20) with Lenalidomide Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-3724 (CD20) monotherapy Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-3724 with GEMOX (CD20) Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-5111 Details Breast cancer, Cancer | Failed Discontinued |